pipette
ESEspañol

Reversal of trauma-induced monocyte paralysis by IFN-γ fails to prevent ventilator-associated pneumonia, implicating lymphoid deficits in infection risk

Jonas Schmid, Susanne Unger, Athanasios Ziogas, Stefanie Kreutmair, Maud Mayoux, Can Ulutekin, Colin Sparano, Juan Villar-Vesga, Marijne Vermeer, Minqi Lin, Selma Tuzlak, Tobias Wertheimer, Daehong Kim, Stanislav Dergun, Boris Novakovic, Laura Hurtado‐Navarro, Anaísa V. Ferreira, Mariolina Bruno, Marijana Saric, Julien Chabbey, Amir Elalfy, Vanessa Dobernig, Philipp Häne, Cécile Poulain, Fernando P. Canale, Bruno François, Mihai Gheorghe Netea, Antoine Roquilly, Burkhard Becher

Peer-reviewed journalReal-world use

In the authors' words

Abstract Ventilator-associated pneumonia (VAP) remains a frequent and severe complication in critically ill patients. Although interferon-gamma (IFN-γ) has been reported to restore trauma-associated immune defects, the PREV-HAP trial (ClinicalTrials.gov NCT04793568) did not show a benefit of IFN-γ on VAP prevention. To investigate the immunological basis of this therapeutic failure, we performed longitudinal high-dimensional immunoprofiling on 104 trial participants. IFN-γ improved phenotypic and metabolic features of monocyte immune suppression, most notably by increasing HLA-DR expression. Whereas HLA-DR on monocytes is a well-established biomarker for patient outcomes, its modulation via IFN-γ injection did not prevent lung pathology, possibly due to CCR7 induction. In contrast, we identified pre-existing deficits in T- and B-cell subsets in patients who subsequently developed VAP. Together, these findings suggest that monocytic HLA-DR expression reflects the immune status rather than directly influencing VAP susceptibility, and that lymphoid immune alterations may represent more relevant determinants of infection risk in ventilated patients.

Main resultThe abstract does not state a limitation.

Appeared: Monday, November 2. Nature Communications. Peer-reviewed journal.

DOI: 10.1038/s41467-026-78844-8